211 related articles for article (PubMed ID: 33651882)
21. Mutations of factor H impair regulation of surface-bound C3b by three mechanisms in atypical hemolytic uremic syndrome.
Lehtinen MJ; Rops AL; Isenman DE; van der Vlag J; Jokiranta TS
J Biol Chem; 2009 Jun; 284(23):15650-8. PubMed ID: 19351878
[TBL] [Abstract][Full Text] [Related]
22. Complement Genetic Variants and FH Desialylation in
Gómez Delgado I; Corvillo F; Nozal P; Arjona E; Madrid Á; Melgosa M; Bravo J; Szilágyi Á; Csuka D; Veszeli N; Prohászka Z; Sánchez-Corral P
Front Immunol; 2021; 12():641656. PubMed ID: 33777036
[TBL] [Abstract][Full Text] [Related]
23. Novel C3 mutation p.Lys65Gln in aHUS affects complement factor H binding.
Volokhina E; Westra D; Xue X; Gros P; van de Kar N; van den Heuvel L
Pediatr Nephrol; 2012 Sep; 27(9):1519-24. PubMed ID: 22669319
[TBL] [Abstract][Full Text] [Related]
24. Anti-factor H autoantibodies in C3 glomerulopathies and in atypical hemolytic uremic syndrome: one target, two diseases.
Blanc C; Togarsimalemath SK; Chauvet S; Le Quintrec M; Moulin B; Buchler M; Jokiranta TS; Roumenina LT; Fremeaux-Bacchi V; Dragon-Durey MA
J Immunol; 2015 Jun; 194(11):5129-38. PubMed ID: 25917093
[TBL] [Abstract][Full Text] [Related]
25. Unraveling the Effect of a Potentiating Anti-Factor H Antibody on Atypical Hemolytic Uremic Syndrome-Associated Factor H Variants.
Dekkers G; Brouwer MC; Jeremiasse J; Kamp A; Biggs RM; van Mierlo G; Lauder S; Katti S; Kuijpers TW; Rispens T; Jongerius I
J Immunol; 2020 Oct; 205(7):1778-1786. PubMed ID: 32848031
[TBL] [Abstract][Full Text] [Related]
26. Disease-associated N-terminal complement factor H mutations perturb cofactor and decay-accelerating activities.
Pechtl IC; Kavanagh D; McIntosh N; Harris CL; Barlow PN
J Biol Chem; 2011 Apr; 286(13):11082-90. PubMed ID: 21270465
[TBL] [Abstract][Full Text] [Related]
27. Blocking Properdin Prevents Complement-Mediated Hemolytic Uremic Syndrome and Systemic Thrombophilia.
Ueda Y; Miwa T; Gullipalli D; Sato S; Ito D; Kim H; Palmer M; Song WC
J Am Soc Nephrol; 2018 Jul; 29(7):1928-1937. PubMed ID: 29858280
[No Abstract] [Full Text] [Related]
28. A prevalent C3 mutation in aHUS patients causes a direct C3 convertase gain of function.
Roumenina LT; Frimat M; Miller EC; Provot F; Dragon-Durey MA; Bordereau P; Bigot S; Hue C; Satchell SC; Mathieson PW; Mousson C; Noel C; Sautes-Fridman C; Halbwachs-Mecarelli L; Atkinson JP; Lionet A; Fremeaux-Bacchi V
Blood; 2012 May; 119(18):4182-91. PubMed ID: 22246034
[TBL] [Abstract][Full Text] [Related]
29. The Murine Factor H-Related Protein FHR-B Promotes Complement Activation.
Cserhalmi M; Csincsi ÁI; Mezei Z; Kopp A; Hebecker M; Uzonyi B; Józsi M
Front Immunol; 2017; 8():1145. PubMed ID: 28974948
[TBL] [Abstract][Full Text] [Related]
30. Spontaneous hemolytic uremic syndrome triggered by complement factor H lacking surface recognition domains.
Pickering MC; de Jorge EG; Martinez-Barricarte R; Recalde S; Garcia-Layana A; Rose KL; Moss J; Walport MJ; Cook HT; de Córdoba SR; Botto M
J Exp Med; 2007 Jun; 204(6):1249-56. PubMed ID: 17517971
[TBL] [Abstract][Full Text] [Related]
31. Defining the Glycosaminoglycan Interactions of Complement Factor H-Related Protein 5.
Gyapon-Quast F; Goicoechea de Jorge E; Malik T; Wu N; Yu J; Chai W; Feizi T; Liu Y; Pickering MC
J Immunol; 2021 Jul; 207(2):534-541. PubMed ID: 34193601
[TBL] [Abstract][Full Text] [Related]
32. The binding of factor H to a complex of physiological polyanions and C3b on cells is impaired in atypical hemolytic uremic syndrome.
Ferreira VP; Herbert AP; Cortés C; McKee KA; Blaum BS; Esswein ST; Uhrín D; Barlow PN; Pangburn MK; Kavanagh D
J Immunol; 2009 Jun; 182(11):7009-18. PubMed ID: 19454698
[TBL] [Abstract][Full Text] [Related]
33. Complement C3b/C3d and cell surface polyanions are recognized by overlapping binding sites on the most carboxyl-terminal domain of complement factor H.
Hellwage J; Jokiranta TS; Friese MA; Wolk TU; Kampen E; Zipfel PF; Meri S
J Immunol; 2002 Dec; 169(12):6935-44. PubMed ID: 12471127
[TBL] [Abstract][Full Text] [Related]
34. Complement Factor H-Related Proteins FHR1 and FHR5 Interact With Extracellular Matrix Ligands, Reduce Factor H Regulatory Activity and Enhance Complement Activation.
Papp A; Papp K; Uzonyi B; Cserhalmi M; Csincsi ÁI; Szabó Z; Bánlaki Z; Ermert D; Prohászka Z; Erdei A; Ferreira VP; Blom AM; Józsi M
Front Immunol; 2022; 13():845953. PubMed ID: 35392081
[TBL] [Abstract][Full Text] [Related]
35. Statistical Validation of Rare Complement Variants Provides Insights into the Molecular Basis of Atypical Hemolytic Uremic Syndrome and C3 Glomerulopathy.
Osborne AJ; Breno M; Borsa NG; Bu F; Frémeaux-Bacchi V; Gale DP; van den Heuvel LP; Kavanagh D; Noris M; Pinto S; Rallapalli PM; Remuzzi G; Rodríguez de Cordoba S; Ruiz A; Smith RJH; Vieira-Martins P; Volokhina E; Wilson V; Goodship THJ; Perkins SJ
J Immunol; 2018 Apr; 200(7):2464-2478. PubMed ID: 29500241
[TBL] [Abstract][Full Text] [Related]
36. FHR-1 Binds to C-Reactive Protein and Enhances Rather than Inhibits Complement Activation.
Csincsi ÁI; Szabó Z; Bánlaki Z; Uzonyi B; Cserhalmi M; Kárpáti É; Tortajada A; Caesar JJE; Prohászka Z; Jokiranta TS; Lea SM; Rodríguez de Córdoba S; Józsi M
J Immunol; 2017 Jul; 199(1):292-303. PubMed ID: 28533443
[TBL] [Abstract][Full Text] [Related]
37. Complement Regulator FHR-3 Is Elevated either Locally or Systemically in a Selection of Autoimmune Diseases.
Schäfer N; Grosche A; Reinders J; Hauck SM; Pouw RB; Kuijpers TW; Wouters D; Ehrenstein B; Enzmann V; Zipfel PF; Skerka C; Pauly D
Front Immunol; 2016; 7():542. PubMed ID: 27965669
[TBL] [Abstract][Full Text] [Related]
38. Heterogeneity but individual constancy of epitopes, isotypes and avidity of factor H autoantibodies in atypical hemolytic uremic syndrome.
Nozal P; Bernabéu-Herrero ME; Uzonyi B; Szilágyi Á; Hyvärinen S; Prohászka Z; Jokiranta TS; Sánchez-Corral P; López-Trascasa M; Józsi M
Mol Immunol; 2016 Feb; 70():47-55. PubMed ID: 26703217
[TBL] [Abstract][Full Text] [Related]
39. Factor H autoantibodies and deletion of Complement Factor H-Related protein-1 in rheumatic diseases in comparison to atypical hemolytic uremic syndrome.
Foltyn Zadura A; Zipfel PF; Bokarewa MI; Sturfelt G; Jönsen A; Nilsson SC; Hillarp A; Saxne T; Trouw LA; Blom AM
Arthritis Res Ther; 2012 Aug; 14(4):R185. PubMed ID: 22894814
[TBL] [Abstract][Full Text] [Related]
40. Partial Complement Factor H Deficiency Associates with C3 Glomerulopathy and Thrombotic Microangiopathy.
Vernon KA; Ruseva MM; Cook HT; Botto M; Malik TH; Pickering MC
J Am Soc Nephrol; 2016 May; 27(5):1334-42. PubMed ID: 26374608
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
